1. Home
  2. HTH vs SUPN Comparison

HTH vs SUPN Comparison

Compare HTH & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hilltop Holdings Inc.

HTH

Hilltop Holdings Inc.

HOLD

Current Price

$33.83

Market Cap

2.1B

Sector

Finance

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$49.23

Market Cap

2.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HTH
SUPN
Founded
1998
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.9B
IPO Year
2004
2012

Fundamental Metrics

Financial Performance
Metric
HTH
SUPN
Price
$33.83
$49.23
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
$34.00
$61.60
AVG Volume (30 Days)
353.0K
602.1K
Earning Date
01-29-2026
02-24-2026
Dividend Yield
2.12%
N/A
EPS Growth
53.28
N/A
EPS
2.50
N/A
Revenue
$1,259,399,000.00
$681,539,000.00
Revenue This Year
N/A
$8.32
Revenue Next Year
$1.64
$23.36
P/E Ratio
$13.57
N/A
Revenue Growth
7.66
4.54
52 Week Low
$26.67
$29.16
52 Week High
$36.14
$57.65

Technical Indicators

Market Signals
Indicator
HTH
SUPN
Relative Strength Index (RSI) 41.80 52.86
Support Level $34.27 $51.01
Resistance Level $35.37 $52.30
Average True Range (ATR) 0.49 1.38
MACD -0.17 0.05
Stochastic Oscillator 18.96 49.85

Price Performance

Historical Comparison
HTH
SUPN

About HTH Hilltop Holdings Inc.

Hilltop Holdings Inc is a Dallas-based financial holding company. The Company has two primary business units, PCC (banking and mortgage origination) and Securities Holdings (broker-dealer). The banking segment includes the operations of the Bank. The banking segment provides business and consumer banking services from offices located throughout Texas and generates revenue from its portfolio of earning assets. The broker-dealer segment includes the operations of Securities Holdings, which operates through its wholly owned subsidiaries Hilltop Securities, Asset Managment LLC, etc. The broker-dealer segment generates a majority of its revenues from fees and commissions earned from investment advisory and securities brokerage services. Majority of revenue is from Banking Segment.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: